CT or MRI within  days prior to start of study drug
Any prior therapy, radiotherapy (except palliative radiation therapy of  gray [Gy] or less), or major surgery must have been completed >=  weeks prior to start of treatment; all adverse events due to prior therapy have resolved to a grade  or better (except alopecia and lymphopenia) by start of treatment; palliative radiation therapy must have been completed at least  weeks prior to start of treatment; the radiotherapy must not be to a lesion that is included as measurable disease\r\n* NOTE: Prostate cancer patients may continue their luteinizing hormone-releasing hormone (LHRH) agonist\r\n* NOTE: Patients may receive non-protocol treatment after biopsy (if clinically indicated) until they receive notification of results; however, lack of response must be documented prior to registration to Step ; new non-protocol treatment will NOT be permitted as intervening therapy after registration to Step ; the decision to stop the intervening non-protocol treatment will be left up to the treating physician if patient has an aMOI; however, patients will need to be off such therapy for at least  weeks before receiving any MATCH protocol treatment\r\n* NOTE: For patients entering the study via a designated outside laboratory, no intervening systemic non-protocol treatment is permitted after Step  registration; all other eligibility requirements still apply to these patients, including the washouts for prior therapy noted above in this section, the time restrictions outlined, and the eligibility criteria for the intended subprotocol
Prior or concurrent therapy with SSA is permitted; a stable dose at least  months prior to study start and must continue on the stable dose while receiving study treatment; SSA is not considered as systemic treatment
Obtained within  days prior to treatment start: Platelets (UNVPLT) >=   ^/L
Administration of antifungal agents (itraconazole, fluconazole, etc) within  weeks of treatment start or unrecovered adverse events (AEs) due to agents administered more than  weeks of treatment start
Prior or concomitant treatments:\r\n* Prior treatment with ibrutinib\r\n* The following cancer treatments:\r\n** Chemotherapy or biological therapy within  days prior to start of treatment\r\n** Immunological therapy, radiation therapy, or hormonal therapy within  days prior to start of treatment\r\n** Major surgery within  days prior to start of treatment\r\n** Subjects who have unresolved toxicity (>= grade ) from prior anti-cancer therapy, unless that event is thought to be due to disease progression\r\n* Any investigational agent, including small molecule agents, within  days prior to start of study treatment\r\n* Any of the following with  days prior to start of study treatment:\r\n** B-cell receptor pathway inhibitor;\r\n** CYPA inhibitors (such as fluconazole, ketoconazole, and clarithromycin);\r\n** Potent CYPA inducers (e.g., rifampin, phenytoin, carbamazepine or St. John's wort);\r\n** Warfarin or requires the use of warfarin (due to potential drug-drug interactions that may potentially increase the exposure of warfarin and complications of this effect);\r\n** Antiretroviral medications\r\n** Antibiotics, antifungals, or antivirals to treat an active infection (prophylactic antibiotics allowed)\r\n* Subjects who are unable or unwilling to discontinue use of prohibited medications, including medications with CYP interactions\r\n* Subject has received prior treatment with allogeneic stem cell transplant or solid organ transplant (except for cornea) for any indication
Participants may not be receiving any other non-Food and Drug Administration (FDA) approved study agents at the start of conditioning for stem cell transplantation; patients may receive non-FDA approved agents at the time of screening/enrollment as long as such agent(s) will be discontinued by the start of conditioning for transplantation
Must start the study treatment no more than  days from the last dose of RT (if administered) and no more than  days from the date of surgical removal of nodal metastases
Radiation therapy within  weeks of study treatment start
Patients under chronic treatment with systemic corticosteroids or other immunosuppressive drugs (e.g. cyclosporine) for a period of at least  weeks and whose treatment was not stopped  week prior to start of the study treatment (day  [D] of cycle )
Prior radiation within  days before start of study registration
Patients must be able to start treatment within  days of randomization.
Treatment with any CTLA antibody within  weeks of the start of study drug.
Have had significant active cardiac disease within  months prior to the start of study treatment, including any of the following:
Albumin >=  g/dL and documented within  days prior to registration and within  days prior to the start of treatment
Any prior radiation must have been completed at least  days prior to the start of study drugs, and patients must have recovered from any acute adverse effects prior to the start of study treatment
Inability to start the protocol treatment within  month after study enrollment
Measurable disease before start of pre-study nivolumab treatment
Hematologic inclusion within  weeks of start of treatment
Concomitant therapies that cannot be discontinued or switched to a different medication prior to study entry that are known to increase serum phosphate levels are not permitted within  weeks prior to start of study treatment)
Patients must be able to start treatment within  days of randomization.
Patients must be able to start treatment (androgen suppression [AS] or radiation) within  days of study registration
Cohort #: prior treatment with ibrutinib is allowed; patients should not have received any anti-lymphoma therapy within  weeks from start of study treatment, with the exception of ibrutinib
Has received prior RT within  weeks of start of study treatment
Patients should be off any prior treatment or line of therapy for  weeks prior to start study with the exception of hydrea (hydroxyurea)
Has a history of arterial thromboembolism within  months of start of study drug
Patients must start therapy within  calendar days of registration
Prior chemotherapy or radiation must have concluded >=  days prior to the start of study treatment
Change in chemotherapy or hormone therapy within  weeks of the start of the study
Have peripheral blood levels of IgG anti-?-glucan antibody (ABA) of ?  mcg/mL as determined by an ELISA test within  days prior to start of study treatment
STUDY TREATMENT: Able to start study treatment in less than or equal to  days after completion of chemoradiation
Agreement to use adequate contraception from  weeks before the start of treatment with Minnelide and until  days after completion of treatment.
Prior radiation treatment less than  months from the planned start of reirradiation of any part of the intended treatment volume
Cancer chemotherapy within  weeks prior to start of daratumumab treatment (exception hydroxyurea). Use of hydroxyurea to control proliferative disease will be allowed prior to starting therapy on study and for  days during cycle - (maximum daily dose of  gm)
Surgery, radiation or chemotherapy within  weeks of proposed step  start date
Long-acting somatostatin analogue treatment within  days of proposed step  start date
Prior treatment with bendamustine (within  months of the start of study treatment). Subjects with prior bendamustine treatment (>  months before the start of study treatment) are eligible if they meet the following criteria:
Hormonal treatment within  weeks prior to start of study treatment (continued use of anti-androgens and/or gonadorelin analogues for treatment of prostate cancer permitted); radiotherapy within  weeks prior to enrolment; palliative radiation to target organs may be allowed up to  weeks prior to enrolment, as long as there are other target lesions that can be monitored for response to study treatment
Hemoglobin (Hgb) >=  g/dL, within  days start of study start
Serum total bilirubin =< . x ULN, within  days start of study start
Serious persistent infection within  days prior to the start of study medication.
Radiation therapy within  weeks prior to start of olaparib treatment (includes radiation targeting bone metastases) or radionuclide treatment within  weeks of treatment start.
INCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Patients must be off chemotherapy for a minimum of  weeks prior to start of treatment; targeted therapies must be stopped at least  days prior to start of lymphodepletion
Prior anti-lymphoma therapy (chemotherapy, immunotherapy or other investigational agent) within  weeks prior to start of study treatment (corticosteroid treatment at doses of ? mg/day, G-CSF or GM CSF are permitted up to  weeks prior to start of study treatment.). Note: excluding pre-treatment with rituximab as part of this study
The subject has had evidence within  years of the start of study treatment of another malignancy which required systemic treatment
Prior treatment with chemotherapy or immunotherapy within  days prior to enrollment. Subjects receiving palliative radiation to CNS disease within  days may be eligible with PI approval. If the most recent treatment line is an EGFR-TKI, the washout period is a minimum of  days before the start of paclitaxel/selumetinib (i.e. treatment with the EGFR-TKI may continue until  days before start of study treatment). For other targeted therapy agents, the washout period will be  half-lives, prior to start of treatment on study.
Study treatment both planned and able to start within  days of randomisation.
Hormonal treatment within  weeks prior to start of study treatment
Patients must be registered prior to the start of treatment
The date protocol therapy is projected to start must be no later than  days after the date of study registration
History of cardiac infarction within the past  months prior to the start of study treatment
Dental evaluation with management prior to start of radiation
Flucytosine within  weeks prior to start of study treatment
The subject has had evidence within  years of the start of study treatment of another malignancy which required systemic treatment; Note: Subjects with a history of early stage or locally advanced non-metastatic prostate cancer within  years of the start of study treatment may be included in the study
For patients receiving treatment of their AML, MDS or ALL prior to transplantation:\r\n* Interval between the start of a cycle of conventional cytotoxic chemotherapy and the start of conditioning regimen must be at least  days\r\n* Interval between completing treatment with a hypomethylating agent or other non-cytotoxic chemotherapy and the start of conditioning regimen must be at least  days
Patients must not have received prior chemotherapy or radiation for <  weeks prior to start of study treatment
Patients may be entered if they have received prior radiation therapy involving =< % of the bone marrow; any prior radiation therapy must have been administered >=  weeks prior to start of study treatment and the patient must be recovered from the acute toxic effects of the treatment prior to start of study treatment
At least  weeks from prior MF-directed treatment (till the start of study drug)
Patient must have a history and physical within  weeks prior to the start of any protocol therapy (radiation and veliparib)
Optune device application start date must be at least  weeks ( days) from central nervous system (CNS) surgical procedure; excluding ventriculoperitoneal (VP) shunts, endoscopic third ventriculostomy (ETV) for which treatment could start  days post procedure; non-CNS surgical procedures such as but not limited to central venous catheter insertion at the discretion of treating physician and study chair
Participants who have had chemotherapy or radiotherapy within  weeks prior to treatment start or those who have not recovered from adverse events due to agents administered more than  weeks prior to treatment start; hydroxyurea is allowed for symptomatic leukocytosis during screening, lead in, and cycle  only if clinically necessary; a total white blood cell (WBC) count <  x ^/L prior to first dose of decitabine on trial is required; prior leukapheresis and/or prior or concurrent treatment with hydroxyurea to achieve this level are allowed
Prior hypomethylating agent (HMA) therapy is allowed, however this study excludes: () patients whose relapse occurred on HMA-based therapy immediately prior to this study and () patients who experience disease progression (see definition below) while receiving HMA-based therapy within the last  weeks prior to treatment start on study; disease progression is defined as either: () patients with MDS who have evidence of initial progression to AML (defined by the presence of >= % blasts in peripheral blood or bone marrow) while receiving HMA-based therapy within the last  weeks prior to treatment start on study; OR () patients with AML who have evidence of progressive disease according to European Leukemia Net (ELN)  criteria (e.g. > % increase in marrow blasts over baseline or > % increase in peripheral blasts to >  x^/L [> ,/uL] [in absence of differentiation syndrome]) while receiving HMA-based therapy within the last  weeks prior to treatment start on study\r\n* (Note: Patients who relapse post-transplant who received HMA treatment prior to transplant are eligible for study)
Patients must be registered prior to the start of treatment
The date protocol therapy is projected to start must be no later than  days after the date of study registration
Prior radiation treatment less than  months from planned start of re-irradiation of any part of the intended treatment volume
Normal left ventricular function as evaluated by echocardiograph within  weeks of start of protocol therapy
Evidence of suspicious microcalcifications in the breast prior to the start of radiation
Cancer chemotherapy within four weeks prior to start of MCLA-;
Has been receiving: radiotherapy, chemotherapy, or molecularly-targeted agents or tyrosine kinase inhibitors within  weeks or  half-lives (whichever is longer) of the start of study treatment; immunotherapy/monoclonal antibodies within  weeks of the start of study treatment; nitrosoureas, antibody-drug conjugates, or radioactive isotopes within  weeks of the start of study treatment.
Any prior radiation must have been completed at least  days prior to the start of study drugs, and patients must have recovered from any acute adverse effects prior to the start of study treatment
Patients with proliferative disease can be cytoreduced with cytotoxic chemotherapy at investigators discretion, but there should be at least a  day window between start of cytoreductive therapy and start of daratumumab
Study treatment both planned and able to start within  days of randomisation
Patients who have received chemo-, hormone-, radio or immunotherapy or therapy with monoclonal antibodies or small tyrosine kinase inhibitors within the past  days prior to start of treatment or those who have not recovered from adverse events attributed to the agent to grade  or baseline\r\n* Exceptions for prior treatments are:\r\n** Hydroxyurea for increased blast count (no washout period required; it can be continued throughout the first cycle of therapy)\r\n** Leukapheresis for leukocytosis (no wash out period required; it can be continued during the study)\r\n*** Note: If patient is registered prior to completion of washout, start date of treatment will need to be confirmed prior to registration; please see assigned quality assurance monitor (QAM) with questions
Therapy for underlying malignancy within  weeks prior to start of study treatment
Cancer immunotherapy within four weeks prior to start of daratumumab treatment (exception blinatumomab within two weeks prior)
Radiation treatment within  weeks prior to treatment start
Radiation treatment within  weeks prior to treatment start
Have had significant active cardiac disease within  months prior to the start of study treatment
No active symptoms related to carcinoid syndrome during the last  months prior to start of study treatment.
Pretreatment with interferon as last treatment prior to start of study treatment.
Cohort a & b patients only: an interval of at least  weeks between prior surgical resection to start of study therapy, or one week for stereotactic biopsy to start of study treatment
Platelets >=  /uL, specimens must be collected within  days prior to the start of study treatment
Use of a protease inhibitor for any indication within three months prior to start of study treatment
Subjects who have received systemic anticancer therapy within  weeks before the start of study treatment; mitomycin C or nitrosoureas must be excluded within  weeks before the start of study treatment
No brain radiation therapy >  weeks before planned start of protocol treatment
No chemotherapy for >  weeks before planned start of protocol treatment
History of any of the following within  months prior to start of MLN:
More than one relapse, secondary glioblastoma and prior treatment with bevacizumab are excluded. An interval of at least  weeks from the completion of radiation therapy to start of study treatment is required.
Receipt of any experimental treatment within  days of start of treatment with afatinib until the end of treatment visit
If PET-negative based on the returned results from centralized review, patients must be planning to begin further treatment within  days of the start of cycle  of R-CHOP; if PET-positive based on the returned results from centralized review, it is important for patients to start IFRT as soon as possible after the end of cycle  of R-CHOP; they should be planning to initiate IFRT followed by yttrium- ibritumomab tiuxetan within  days of the start of cycle  of R-CHOP
Evidence within  years of the start of study treatment of another malignancy which required systemic treatment
Central review of pathology is required for study participation, but not required prior to enrollment or start of treatment in order to avoid delay. If the results of central pathology review are not available prior to the start of study treatment, the confirmation of diagnosis of ATC at the local laboratory is mandatory prior to scheduled start of treatment with lenvatinib.
Patients must be suitable to start treatment with single agent chemotherapy based on physician's choice
Chemotherapy within  days or at least  half-lives prior to the planned start of study treatment; radiation outside the thorax within  days prior to the planned start of study treatment or thoracic radiation; antibody based therapy or investigational therapy within  days prior to the planned start of study treatment.
Last dose of therapeutic glucocorticosteroids given greater than  days prior to start of study treatment.
serious persistent infection within  days prior to the start of study medication;
Therapy for underlying malignancy within  weeks prior to start of study treatment:
Subject is taking warfarin at start of treatment or within  months prior to start of study treatment
Patients who have received a taxane based treatment or abiraterone, within  weeks before start of study treatment.
The subject has had within  years before the start of study treatment evidence of another malignancy which required systemic treatment
Radiation therapy within four weeks prior to start of study treatment (day -)
The interval between last PD-(L) directed treatment and start of study treatment should be at least  days.
Subjects who have started oral or parenteral anticoagulation therapy within  weeks before the start of anetumab ravtansine until end of treatment visit.
Completion of all therapy for the treatment of cancer  weeks before the start of study therapy and recovered.
Study treatment both planned and able to start within  days after randomisation.
Has a history of arterial thromboembolism within  months of start of study drug
Radiation therapy planned to start =<  weeks after surgery and at least  days after the start of minocycline
Patients on steroids for symptom management must be on a stable dose for  days prior to start of treatment
Completion of previous chemotherapy regimen >=  weeks prior to the start of study treatment
Administration of any therapy for MDS (conventional or investigational) must be completed by  weeks prior to of the first dose of study drug; in the event of rapidly proliferative disease use of hydroxyurea is permitted until  hours before the start of study treatment. Toxicities associated with prior MDS therapy must have recovered to grade  or less prior to start of treatment.
The subject has had evidence within  years of the start of study treatment of another malignancy which required systemic treatment
The participant has had evidence within  years of the start of study treatment of another malignancy which required systemic treatment
Laboratory evaluations;\r\n* Semen analysis (patients will not be excluded if they do not wish to have an analysis or their insurance denies the claim) (prior to start of radiation)\r\n* Follicle-stimulating hormone (prior to start of radiation\r\n* Luteinizing Hormone (prior to start of radiation)\r\n* Lactate Dehydrogenase (prior to start of radiation)\r\n* Human chorionic gonadotropin (prior to start of radiation)\r\n* Complete blood count (prior to start of radiation)\r\n* Alpha-fetoprotein (prior to start of radiation)
Patients may not have had prior radiotherapy to > % of bone marrow; standard rectal cancer chemoradiation will not exclude subject from study protocol; any radiation must have concluded >=  weeks prior to start of protocol treatment
Patients expected to survive longer than  months from the start date of the protocol treatment
No prior radiation treatment to the affected spine, or sacral region; prior chemotherapy is allowed within  days of start of treatment
Regular treatment with corticosteroids during the  weeks prior to the start of Cycle 
Evidence of suspicious microcalcifications in the breast prior to start of radiation
For patients previously treated with other agents approved for the treatment of prostate cancer (-? reductase inhibitors, estrogens, others), discontinuation of therapy must have occurred ? weeks prior to start of study drug.
Have peripheral blood levels of IgG anti-?-glucan antibody (ABA) of ?  mcg/mL as determined by an ELISA test within  days prior to start of study treatment
For patients with no prior chemotherapy, treatment must start within  days of\r\ndefinitive surgery or as indicated if enrolled on therapeutic study
Prior treatment with bendamustine (within  years of the start of Cycle )
Must be able to start treatment with radiation therapy (RT) within  weeks or  working days at a qualified center (to be defined by the Radiation Oncology chair) and to start TMZ prescribed at a participating center within  weeks or  working days of randomization
Eligible for and agree to BM aspirate prior to treatment start
No prior treatment for ALL, except steroids or hydroxyurea (stopped within  hours before start of protocol treatment)
Treatment must start not more than  days from diagnosis of metastatic retinoblastoma
At least  months from prior anti-EGFR therapy prior to start of study treatment
Patients with previous anti-cancer chemotherapy, immunotherapy or investigational agents =<  weeks prior to the first day of study defined treatment; NSCLC patients with EGFR mutation can enroll within  days of discontinuing EGFR-TKI; palliative radiation <  week before the start of treatment (lesions subjected to radiotherapy may not be used as target lesions); patients who receive gamma knife radiosurgery for brain metastases within  week prior to treatment start
For disease specific studies: the subject has had evidence within  years of the start of study treatment of another malignancy which required systemic treatment
Patients under chronic treatment with systemic corticoids or other immunosuppressive drugs (e.g., cyclosporine) for a period of at least  weeks and whose treatment was not stopped  week prior to the start of the study treatment (i.e., D of Cycle )
For disease specific studies: the subject has had evidence within  years of the start of study treatment of another malignancy which required systemic treatment
History of heart problems or thrombosis within  months prior to study start.
. Patients must start treatment in the extension protocol within  weeks of their last injection administered in the core protocol.
The subject has had evidence within  years of the start of study treatment of another malignancy which required systemic treatment
Any prior anti-cancer treatment such as chemotherapy, immunomodulatory drug therapy, etc., received within  days prior to start of CA-
No treatment interruption of Bevacizumab treatment greater than  consecutive cycles ( days) between the start of first-line treatment to start of Cycle  of second line treatment
One of the following:\r\n* Cytotoxic chemotherapy, alemtuzumab, or an adequate course of -azacitidine or decitabine within  months prior to start of conditioning; or\r\n* Previous BMT within  months prior to start of conditioning\r\n** Note: Patients who have received treatment outside of these windows may be eligible if it is deemed sufficient to reduce graft rejection risk; this will be decided on a case-by-case basis by the PI or co-PI
Must agree to undergo two medically supervised pregnancy tests prior to starting study therapy with either Rd or MPT. The first pregnancy test will be performed within - days prior to the start of Rd or MPT and the second pregnancy test will be performed within  hours prior to the start of Rd or MPT. She must also agree to ongoing pregnancy testing during the course of the study and after the end of study therapy. This applies even if the patient practices complete and continued sexual abstinence.
Evidence of recurrence of rectal cancer prior to the start of study treatment
PRIOR TO START OF TREATMENT:
Will not start treatment for at least  weeks AND
Patients must have had a transrectal ultrasound (TRUS)/endoscopic ultrasound (TEUS) staging within two months prior to treatment start
SUBJECT: A child has plans to start a new treatment for attention/memory problems in the next  months.
An episode of vomiting or retching within  hours before the start of the initial treatment with chemotherapy
Patient must be above the age of  month as of the start date of study treatment.
Patient has hemodynamic instability within  hours before the start of study treatment.
Patient used any medication that increases the risk of bleeding within  hours before the start of study treatment.
Patient has taken phenothiazines (prochlorperazine, fluphenazine, perphenazine, thiethylperazine, chlorpromazine, etc.) for any indication within the last  hours prior to the start of treatment with study drug
In patients without cGVHD, transplant must have occurred - days before the start of study drug
Participants take supplements or foods that are labelled as containing green tea for  weeks before start of treatment
Intention to start therapy
Received treatment with anti-CTLA- antibody within  days prior to the start of CMP- dosing on WD.
Cohort  only: more than one prior treatment with VEGFR active multikinase inhibitor prior to original start of lenvatinib
Platelets >= ,/L, within  weeks prior to study start
Patients are eligible to be treated with RT and plan to start treatment
Patients are eligible to be treated with RT or CRT and plan to start treatment
